Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress (Everolimus) Versus Rapamune (Sirolimus) in Combination With Low Dose Neoral(Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.

Next Previous
X
Search
Trial Profile

A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress (Everolimus) Versus Rapamune (Sirolimus) in Combination With Low Dose Neoral(Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Antithymocyte globulin; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Nov 2021 Status changed from active, no longer recruiting to completed.
    • 09 May 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
    • 09 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top